Literature DB >> 31626359

Antibiotic sensitivity and clinical outcomes in staphylococcal scalded skin syndrome.

Zixiao Wang1, Jessica L Feig1, Diana B Mannschreck1, Bernard A Cohen1.   

Abstract

Staphylococcal scalded skin syndrome causes widespread skin denudation primarily in infants < 1 year old. Selection of empiric therapy is complicated by rising rates of antibiotic resistance in community-acquired staphylococcal infections. Consistent with a previous study, this retrospective review found that SSSS-associated isolates were more likely to be clindamycin-resistant and less likely to be methicillin-resistant compared to overall staphylococcal infections. We favor cephalosporins and penicillinase-resistant penicillins (eg, oxacillin) for empiric management of SSSS, with consideration of adding MRSA coverage in communities with high MRSA prevalence or failure to improve following several days of treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990Staphylococcus aureuszzm321990; MRSA; SSSS; antibiotic resistance; scalded skin syndrome

Mesh:

Substances:

Year:  2019        PMID: 31626359     DOI: 10.1111/pde.14014

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  3 in total

Review 1.  Management of Infectious Emergencies for the Inpatient Dermatologist.

Authors:  Tulsi Patel; Krystina Quow; Adela R Cardones
Journal:  Curr Dermatol Rep       Date:  2021-10-06

2.  The Role of Gram Staining in Staphylococcal Scalded Skin Syndrome.

Authors:  Dan Morgenstern-Kaplan; Rodrigo Fonseca-Portilla; Enrique Konstat-Korzenny; Ariel Cohen-Welch
Journal:  Cureus       Date:  2020-04-10

3.  Antibiotic-resistant profile and the factors affecting the intravenous antibiotic treatment course of generalized Staphylococcal Scalded Skin Syndrome: a retrospective study.

Authors:  Tao Yang; Jiangyi Wang; Junya Cao; Xinyue Zhang; Yun Lai; Longnian Li; Xiaoying Ye; Cong You
Journal:  Ital J Pediatr       Date:  2021-08-06       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.